Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2012, Article ID 147896, 9 pages
http://dx.doi.org/10.1155/2012/147896
Research Article

Synergistic Cytotoxic Effects of Ganoderma lucidum and Bacillus Calmette Guérin on Premalignant Urothelial HUC-PC Cells and Its Regulation on Proinflammatory Cytokine Secretion

1School of Nursing, The Hong Kong Polytechnic University, Hung Hom, Hong Kong
2Department of Medical Science, Tung Wah College, Homantin, Hong Kong
3Department of Surgery, The Chinese University of Hong Kong, Shatin, Hong Kong

Received 9 May 2012; Accepted 12 July 2012

Academic Editor: Jae Youl Cho

Copyright © 2012 John Wai-man Yuen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Simon, E. Eltze, K. L. Schäfer et al., “Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells,” Cancer Research, vol. 61, no. 1, pp. 355–362, 2001. View at Google Scholar · View at Scopus
  2. I. Sakai, H. Miyake, K. I. Harada, I. Hara, T. A. Inoue, and M. Fujisawa, “Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ,” International Journal of Urology, vol. 13, no. 11, pp. 1389–1392, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. J. J. Patard, F. Saint, F. Velotti, C. C. Abbou, and D. K. Chopin, “Immune response following intravesical bacillus Calmette-Guérin instillations in superficial madder cancer: a review,” Urological Research, vol. 26, no. 3, pp. 155–159, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. A. T. Ludwig, J. M. Moore, Y. Luo et al., “Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for bacillus Calmette-Guérin-induced antitumor activity,” Cancer Research, vol. 64, no. 10, pp. 3386–3390, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. D. L. Paterson and A. Patel, “Bacillus Calmette-Guérin (BCG) immunotherapy for bladder cancer: review of complications and their treatment,” Australian and New Zealand Journal of Surgery, vol. 68, no. 5, pp. 340–344, 1998. View at Google Scholar · View at Scopus
  6. E. C. de Boer, W. H. de Jong, P. A. Steerenberg et al., “Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer,” Cancer Immunology Immunotherapy, vol. 34, no. 5, pp. 306–312, 1992. View at Google Scholar · View at Scopus
  7. R. J. Sylvester, A. P. M. van der Meijden, W. Oosterlinck, W. Hoeltl, and A. V. Bono, “The side effects of bacillus Calmette-Guérin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European organisation for research and treatment of cancer genito-urinary group phase III trial,” European Urology, vol. 44, no. 4, pp. 423–428, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. E. A. Bookland, S. Swaminathan, R. Oyasu, K. W. Gilchrist, M. Lindstrom, and C. A. Reznikoff, “Tumorigenic transformation and neoplastic progression of human uroepithelial: cells after exposure in vitro to 4-aminobiphenyl or its metabolites,” Cancer Research, vol. 52, no. 6, pp. 1606–1614, 1992. View at Google Scholar · View at Scopus
  9. J. W. M. Yuen and M. D. I. Gohel, “Anticancer effects of Ganoderma lucidum: a review of scientific evidence,” Nutrition and Cancer, vol. 53, no. 1, pp. 11–17, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. Q. Y. Lu, Y. S. Jin, Q. Zhang et al., “Ganoderma lucidum extracts inhibit growth and induce actin polymerization in bladder cancer cells in vitro,” Cancer Letters, vol. 216, no. 1, pp. 9–20, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. J. W. M. Yuen, M. D. I. Gohel, and D. W. T. Au, “Telomerase-associated apoptotic events by mushroom Ganoderma lucidum on premalignant human urothelial cells,” Nutrition and Cancer, vol. 60, no. 1, pp. 109–119, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. J. W. M. Yuen, M. D. I. Gohel, and C. F. Ng, “The differential immunological activities of Ganoderma lucidum on human pre-cancerous uroepithelial cells,” Journal of Ethnopharmacology, vol. 135, no. 3, pp. 711–718, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. J. W. M. Yuen and M. D. I. Gohel, “The dual roles of Ganoderma antioxidants on urothelial cell DNA under carcinogenic attack,” Journal of Ethnopharmacology, vol. 118, no. 2, pp. 324–330, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Zhao, M. G. Wientjes, and J. L. S. Au, “Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses,” Clinical Cancer Research, vol. 10, no. 23, pp. 7994–8004, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Zhang, H. E. Khoo, and K. Esuvaranathan, “Effects of bacillus Calmette-Guérin and interferon-α-2B on human bladder cancer in vitro,” International Journal of Cancer, vol. 71, no. 5, pp. 851–857, 1997. View at Publisher · View at Google Scholar
  16. M. C. Filion, P. Lépicier, A. Morales, and N. C. Phillips, “Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells,” British Journal of Cancer, vol. 79, no. 2, pp. 229–235, 1999. View at Google Scholar · View at Scopus
  17. A. Sasaki, S. Kudoh, K. Mori, N. Takahashi, and T. Suzuki, “Are BCG effects against urinary bladder carcinoma cell line T24 correlated with apoptosis in vitro?” Urologia Internationalis, vol. 59, no. 3, pp. 142–148, 1997. View at Google Scholar · View at Scopus
  18. R. F. M. Bevers, K. H. Kurth, and D. H. J. Schamhart, “Role of urothelial cells in BCG immunotherapy for superficial bladder cancer,” British Journal of Cancer, vol. 91, no. 4, pp. 607–612, 2004. View at Google Scholar · View at Scopus
  19. M. Mehmut, K. Takeda, M. Abe et al., “Fas ligand and TNF-related apoptosis-inducing ligand induction on infiltrating lymphocytes in bladder carcinoma by bacillus Calmette-Guérin treatment,” Urologia Internationalis, vol. 75, no. 1, pp. 80–87, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. T. J. Kemp, A. T. Ludwig, J. K. Earel et al., “Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guérin (BCG) results in the release of functional soluble TRAIL/Apo-2L,” Blood, vol. 106, no. 10, pp. 3474–3482, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Luo, X. Chen, and M. A. O'Donnell, “Role of Th1 and Th2 cytokines in BCG-induced IFN-γ production: cytokine promotion and simulation of BCG effect,” Cytokine, vol. 21, no. 1, pp. 17–26, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. K. G. Nepple, H. A. Aubert, M. R. Braasch, and M. A. O'Donnell, “Combination of BCG and interferon intravesical immunotherapy: an update,” World Journal of Urology, vol. 27, no. 3, pp. 343–346, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. H. Gu and M. A. Belury, “Selective induction of apoptosis in murine skin carcinoma cells (CH72) by an ethanol extract of Lentinula edodes,” Cancer Letters, vol. 220, no. 1, pp. 21–28, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Nonaka, H. Shibata, M. Nakai et al., “Anti-tumor activities of the antlered form of Ganoderma lucidum in allogeneic and syngeneic tumor-bearing mice,” Bioscience, Biotechnology and Biochemistry, vol. 70, no. 9, pp. 2028–2034, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Zhao, Q. Zhang, L. Zhao, X. Huang, J. Wang, and X. Kang, “Spore powder of Ganoderma lucidum improves cancer-related fatigue in breast cancer patients undergoing endocrine therapy: a pilot clinical trial,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 809614, 8 pages, 2012. View at Publisher · View at Google Scholar
  26. W. T. Chung, S. H. Lee, J. D. Kim et al., “Effect of mycelial culture broth of Ganoderma lucidum on the growth characteristics of human cell lines,” Journal of Bioscience and Bioengineering, vol. 92, no. 6, pp. 550–555, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. H. S. Chen, Y. F. Tsai, S. Lin et al., “Studies on the immuno-modulating and anti-tumor activities of Ganoderma lucidum (Reishi) polysaccharides,” Bioorganic and Medicinal Chemistry, vol. 12, no. 21, pp. 5595–5601, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Miyazaki, K. Kawai, T. Oikawa et al., “Uroepithelial cells can directly respond to Mycobacterium bovis bacillus Calmette-Guérin through Toll-like receptor signalling,” British Journal of Urology International, vol. 97, no. 4, pp. 860–864, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. M. A. O'Donnell, J. Krohn, and W. C. DeWolf, “Salvage intravesical therapy with interferon-α2B plus low dose bacillus Calmette-Guérin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guérin alone previously failed,” Journal of Urology, vol. 166, no. 4, pp. 1300–1304, 2001. View at Google Scholar · View at Scopus
  30. B. Louie, S. Rajamahanty, J. Won, M. Choudhury, and S. Konno, “Synergistic potentiation of interferon activity with maitake mushroom d-fraction on bladder cancer cells,” British Journal of Urology International, vol. 105, no. 7, pp. 1011–1015, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. R. G. Jones and C. B. Thompson, “Tumor suppressors and cell metabolism: a recipe for cancer growth,” Genes and Development, vol. 23, no. 5, pp. 537–548, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Y. Ping, C. L. Wu, and D. S. Yu, “Sunitinib can enhance BCG mediatedcytotoxicity to transitional cell carcinoma through apoptosis pathway,” Urologic Oncology: Seminars and Original Investigations. In press. View at Publisher · View at Google Scholar · View at Scopus
  33. D. S. Yu, S. Y. Ping, C. L. Wu, H. I. Chen, S. Y. Chang, and C. P. Ma, “The feasibility of BCG and sunitinib combination therapy for transitional cell carcinoma,” Urological Science, vol. 22, no. 1, pp. 19–27, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Horiguchi, K. Kuroda, J. Nakashima, M. Murai, and K. Umezawa, “Antitumor effect of a novel nuclear factor-κB activation inhibitor in bladder cancer cells,” Expert Review of Anticancer Therapy, vol. 3, no. 6, pp. 793–798, 2003. View at Google Scholar · View at Scopus
  35. L. M. Lamale, S. K. Lutgendorf, M. B. Zimmerman, and K. J. Kreder, “Interleukin-6, histamine, and methylhistamine as diagnostic markers for interstitial cystitis,” Urology, vol. 68, no. 4, pp. 702–706, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. B. Amann, F. G. E. Perabo, A. Wirger, H. Hugenschmidt, and W. Schultze-Seemann, “Urinary levels of monocyte chemo-attractant protein-1 correlate with tumour stage and grade in patients with bladder cancer,” British Journal of Urology, vol. 82, no. 1, pp. 118–121, 1998. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Reale, R. Intorno, R. Tenaglia et al., “Production of MCP-1 and RANTES in bladder cancer patients after bacillus Calmette-Guérin immunotherapy,” Cancer Immunology, Immunotherapy, vol. 51, no. 2, pp. 91–98, 2002. View at Publisher · View at Google Scholar · View at Scopus